arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Bioventus Inc.

BVS
$13.59 ▼ -0.07 (-0.51%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
26 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
57
Health
Fair
Bearish
auto_awesome

Analytical Summary

Bioventus Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $922.3M
Dividend Yield
Revenue Growth 3.8%
Op. Margin 12.5%
ROIC 9.9%
FCF / Share $0.28
Trailing P/E 27.7x
Price / Book 4.0x
FCF Yield 2.1%
Debt / Equity 1.01
info Valuation on last close. End-of-day price, Sep 23, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$153.21M
↑ +3.8%
Net Income Profit after all expenses
$33.44M
↑ +348.3%
Operating Margin Operating profit as % of sales
12.5%
↑ +95.9% 55th
FCF / Share Free cash flow per share
$0.28
↑ +124.3%
Long-Term Debt Long-term obligations
$229.70M
↓ -9.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
56
Returns
75
Financial Health
17
Cash Quality
92

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 26 quarters